299 related articles for article (PubMed ID: 9804374)
1. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract][Full Text] [Related]
2. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.
Kraus JA; Wenghoefer M; Glesmann N; Mohr S; Beck M; Schmidt MC; Schröder R; Berweiler U; Roggendorf W; Diete S; Dietzmann K; Heuser K; Müller B; Fimmers R; von Deimling A; Schlegel U
J Neurooncol; 2001 May; 52(3):263-72. PubMed ID: 11519857
[TBL] [Abstract][Full Text] [Related]
3. p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme.
Stark AM; Witzel P; Strege RJ; Hugo HH; Mehdorn HM
J Neurol Neurosurg Psychiatry; 2003 Jun; 74(6):779-83. PubMed ID: 12754350
[TBL] [Abstract][Full Text] [Related]
4. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme.
Stark AM; Hugo HH; Witzel P; Mihajlovic Z; Mehdorn HM
Zentralbl Neurochir; 2003; 64(1):30-6. PubMed ID: 12582944
[TBL] [Abstract][Full Text] [Related]
5. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.
Das A; Tan WL; Teo J; Smith DR
J Neurooncol; 2002 Nov; 60(2):117-25. PubMed ID: 12635658
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics of radiographically defined de novo glioblastoma multiforme.
Tortosa A; Ino Y; Odell N; Swilley S; Sasaki H; Louis DN; Henson JW
Neuropathol Appl Neurobiol; 2000 Dec; 26(6):544-52. PubMed ID: 11123721
[TBL] [Abstract][Full Text] [Related]
8. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
Khatri RG; Navaratne K; Weil RJ
J Neurosurg; 2008 Nov; 109(5):842-8. PubMed ID: 18976073
[TBL] [Abstract][Full Text] [Related]
9. Supratentorial glioblastoma in adults: identification of subsets and their clinical correlation.
Sarkar C; Sinha S; Sharma MC; Kumar R; Mehta VS
Brain Tumor Pathol; 2004; 21(1):7-12. PubMed ID: 15696962
[TBL] [Abstract][Full Text] [Related]
10. Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status.
Halatsch ME; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2006; 26(6B):4191-4. PubMed ID: 17201132
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.
Kraus JA; Glesmann N; Beck M; Krex D; Klockgether T; Schackert G; Schlegel U
J Neurooncol; 2000 Jun; 48(2):89-94. PubMed ID: 11083071
[TBL] [Abstract][Full Text] [Related]
13. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.
Burton EC; Lamborn KR; Forsyth P; Scott J; O'Campo J; Uyehara-Lock J; Prados M; Berger M; Passe S; Uhm J; O'Neill BP; Jenkins RB; Aldape KD
Clin Cancer Res; 2002 Jan; 8(1):180-7. PubMed ID: 11801556
[TBL] [Abstract][Full Text] [Related]
14. Primary and secondary glioblastomas: from concept to clinical diagnosis.
Kleihues P; Ohgaki H
Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
[TBL] [Abstract][Full Text] [Related]
15. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
Watanabe K; Tachibana O; Sata K; Yonekawa Y; Kleihues P; Ohgaki H
Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278
[TBL] [Abstract][Full Text] [Related]
17. Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma.
Ushio Y; Tada K; Shiraishi S; Kamiryo T; Shinojima N; Kochi M; Saya H
Front Biosci; 2003 May; 8():e281-8. PubMed ID: 12700122
[TBL] [Abstract][Full Text] [Related]
18. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
Simmons ML; Lamborn KR; Takahashi M; Chen P; Israel MA; Berger MS; Godfrey T; Nigro J; Prados M; Chang S; Barker FG; Aldape K
Cancer Res; 2001 Feb; 61(3):1122-8. PubMed ID: 11221842
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line.
Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T
Anticancer Res; 2001; 21(1A):189-95. PubMed ID: 11299733
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors.
Cheng Y; Ng HK; Ding M; Zhang SF; Pang JC; Lo KW
J Neuropathol Exp Neurol; 1999 Feb; 58(2):120-8. PubMed ID: 10029095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
